Sutro Biopharma (NASDAQ: STRO) is one of 114 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Sutro Biopharma to similar businesses based on the strength of its dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.
Earnings & Valuation
This table compares Sutro Biopharma and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Sutro Biopharma||$38.42 million||-$35.32 million||-1.92|
|Sutro Biopharma Competitors||$897.63 million||$190.37 million||-1.33|
Sutro Biopharma’s rivals have higher revenue and earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings and price targets for Sutro Biopharma and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sutro Biopharma Competitors||832||2772||6049||261||2.58|
Sutro Biopharma currently has a consensus target price of $24.33, indicating a potential upside of 106.74%. As a group, “Biological products, except diagnostic” companies have a potential upside of 32.46%. Given Sutro Biopharma’s stronger consensus rating and higher probable upside, equities analysts clearly believe Sutro Biopharma is more favorable than its rivals.
Insider and Institutional Ownership
47.2% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.7% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Sutro Biopharma and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sutro Biopharma Competitors||-5,144.22%||-64.24%||-27.96%|
Sutro Biopharma Company Profile
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.